{
    "Clinical Trial ID": "NCT02187744",
    "Intervention": [
        "INTERVENTION 1: ",
        "  PF-05280014",
        "  Participants received a loading dose of 8 mg/kg of PF-05280014 on Cycle 1 Day 1. Subsequent infusions followed every 3 weeks with a dose of 6 mg/kg. Taxotere 75 mg/m2 and carboplatin AUC 6 were administered on Day 1 of each cycle.",
        "INTERVENTION 2: ",
        "  Trastuzumab-EU",
        "  Participants received a loading dose of 8 mg/kg of trastuzumab-EU on Cycle 1 Day 1. Subsequent infusions followed every 3 weeks with a dose of 6 mg/kg. Taxotere 75 mg/m2 and carboplatin AUC 6 were administered on Day 1 of each cycle."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically confirmed HER2 overexpressing invasive breast cancer.",
        "  Plan for definitive surgical resection of breast tumor (i.e., lumpectomy or mastectomy, and sentinel node (SN) biopsy or axillary lymph node dissection (ALND).",
        "  Plan for neoadjuvant chemotherapy.",
        "  Measurable disease in the breast after diagnostic biopsy, defined as longest diameter  2.0 cm.",
        "Exclusion Criteria:",
        "  Bilateral breast cancer.",
        "  Inflammatory breast cancer.",
        "  Presence of known distant metastases.",
        "  Received prior treatment, including chemotherapy, endocrine therapy, biologic therapy, radiation or surgery with the exception of diagnostic biopsy for primary breast cancer."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percentage of Participants With Steady State Drug Concentration Ctrough (Cycle 6 Pre-dose) >20 \u00b5g/mL at Cycle 5.",
        "  The percentage of participants with Cycle 5 Ctrough (Cycle 6 pre-dose) >20 \u03bcg/mL in each treatment group, the denominator being the number of participants in the per protocol population for each treatment group.",
        "  Time frame: Cycle 5",
        "Results 1: ",
        "  Arm/Group Title: PF-05280014",
        "  Arm/Group Description: Participants received a loading dose of 8 mg/kg of PF-05280014 on Cycle 1 Day 1. Subsequent infusions followed every 3 weeks with a dose of 6 mg/kg. Taxotere 75 mg/m2 and carboplatin AUC 6 were administered on Day 1 of each cycle.",
        "  Overall Number of Participants Analyzed: 101",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of participants  92.1        (85.0 to 96.5)",
        "Results 2: ",
        "  Arm/Group Title: Trastuzumab-EU",
        "  Arm/Group Description: Participants received a loading dose of 8 mg/kg of trastuzumab-EU on Cycle 1 Day 1. Subsequent infusions followed every 3 weeks with a dose of 6 mg/kg. Taxotere 75 mg/m2 and carboplatin AUC 6 were administered on Day 1 of each cycle.",
        "  Overall Number of Participants Analyzed: 89",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of participants  93.3        (85.9 to 97.5)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 7/113 (6.19%)",
        "  Febrile neutropenia 1/113 (0.88%)",
        "  Neutropenia 1/113 (0.88%)",
        "  Anaemia 0/113 (0.00%)",
        "  Pancytopenia 1/113 (0.88%)",
        "  Proctitis 1/113 (0.88%)",
        "  Device related sepsis 1/113 (0.88%)",
        "  Gastrointestinal infection 0/113 (0.00%)",
        "  Injection site abscess 1/113 (0.88%)",
        "  Tooth infection 0/113 (0.00%)",
        "  Hip fracture 0/113 (0.00%)",
        "  Blood creatinine increased 1/113 (0.88%)",
        "Adverse Events 2:",
        "  Total: 6/112 (5.36%)",
        "  Febrile neutropenia 2/112 (1.79%)",
        "  Neutropenia 1/112 (0.89%)",
        "  Anaemia 1/112 (0.89%)",
        "  Pancytopenia 0/112 (0.00%)",
        "  Proctitis 0/112 (0.00%)",
        "  Device related sepsis 0/112 (0.00%)",
        "  Gastrointestinal infection 1/112 (0.89%)",
        "  Injection site abscess 0/112 (0.00%)",
        "  Tooth infection 1/112 (0.89%)",
        "  Hip fracture 1/112 (0.89%)",
        "  Blood creatinine increased 0/112 (0.00%)"
    ]
}